Cardica, a medical device company, has received 510(k) approval from the US Food and Drug Administration (FDA) for its MicroCutter Xchange 30 device and blue staple cartridge for medium thickness tissue. The company has designed the ...
Tags: Cardica, medical device
A new clinical study has been conducted by Lipotec to assess the anti-wrinkle efficacy of Argireline peptide at a concentration of 2%. The new test shows remarkable improvement of skin appearance after just one week of treatment. The test ...
Tags: Lipotec, anti-wrinkle, Argireline peptide, skin appearance
RegeneRx Biopharmaceuticals, Inc. (OTC: RGRX) ("the Company" or "RegeneRx") announced that it has received Orphan Drug designation from U.S. FDA's Office of Orphan Products Development (OOPD) for its drug candidate, Thymosin beta 4 ...
Tags: RegeneRx Biopharmaceuticals, Orphan Drug designation, Thymosin beta 4
Can-Fite BioPharma Ltd. (TASE:CFBI), (NYSE MKT:CANF), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that its subsidiary OphthaliX Inc. (OTCBB:OPLI) ...
Tags: Can-Fite BioPharma, OphthaliX, placebo-controlled phase III study
The Axios Stent and Delivery System has been approved by the U.S. Food and Drug Administration to treat infected pancreatic cysts that won't drain on their own and could become life threatening, the FDA said in a news release. The ...
Tags: Axios, Stent and Delivery System, infected pancreatic cysts
Tretten (coagulation factor XIII A-Subunit recombinant) has been approved by the U.S. Food and Drug Administration to treat a very rare blood clotting disorder called congenital Factor XIII A-Subunit deficiency. People with the genetic ...
Tags: Tretten, blood clotting disorder
Merck Announces Launch of a New Business Focused on Comprehensive, Evidence-Based Weight Management Interventions in the U.S. WHITEHOUSE STATION, N.J., Dec. 20, 2013--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States ...
Stelis Biopharma and Pieris, a next generation therapeutic protein R&D firm, have started a long-term collaboration for clinical development and commercialization of multiple novel Anticalin-based protein therapeutics worldwide, primarily ...
Nucletron has announced that the first Esteya electronic brachytherapy system in the US has been installed at New York's Memorial Sloan-Kettering Cancer Center. Esteya by Nucletron, an Elekta company, is a new approach for skin cancer ...
Tags: Nucletron, Skin Cancer
W. L. Gore & Associates (Gore) has obtained the US Food and Drug Administration (FDA) approval for its GORE VIABAHN endoprosthesis for the treatment of stenosis or thrombotic occlusion at the venous anastomosis of synthetic arteriovenous ...
Tags: Gore, FDA, GORE VIABAHN, endoprosthesis, AV access
Cook Medical has begun a US clinical trial to evaluate the possibility of removing a new Evolution esophageal fully covered stent after malignant and benign strictures have been treated. In this clinical study, design of the Evolution ...
Tags: Cook Medical, Evolution esophageal fully covered stent
Lipotec achieved silver at the Innovation Zone Best Ingredient award for Juvefoxo peptide. The award recognises active ingredients developments with scientific prowess and the decision of the jury, all international industry experts, took ...
Oculus Innovative Sciences has obtained 510(k) approval from the US Food and Drug Administration (FDA) for its new Microcyn scar management HydroGel, intended to manage old and new hypertrophic and keloid scarring resulting from burns, ...
Bolton Medical, a medical device manufacturer, has initiated its Phase II US clinical trial to study the safety and effectiveness of the Treovance abdominal stent-graft with Navitel delivery system. The first two cases were performed on ...
US-based Bruker has obtained 510(k) clearance from the US Food and Drug Administration (FDA) for its MALDI Biotyper CA system to identify Gram negative bacterial colonies cultured from human specimens. Bruker's MALDI Biotyper CA system ...